Trials that matter: two faces of progress in the treatment of age-related macular degeneration.

Age-related macular degeneration (AMD) is a common ocular condition that may destroy central vision and have a devastating effect on the quality of life of people over the age of 55- Since the population of the United States is now living longer, more people are at risk for developing the disease as the population ages. By age 70, nearly 1 of 3 people shows signs of at least mild AMD on ophthalmologic examination.

作 者：

Epstein,P

刊 名：

Annals of Internal Medicine 

年，卷(期)：

2007vol.146(no.7) 

分类号：

 

关键词：

Antibodies, Monoclonal  Macular Degeneration  Vascular Endothelial Growth Factor A

正文语种：

eng 

基金项目：